The Price Void
PBM black-box opacity. Price-responsive formularies. Essential medication with no exit. The Daraprim experiment — one patent acquisition, all constraints removed simultaneously — produced a 5000% price increase in 24 hours. The framework predicted this structure independently. The experiment already happened.
What happens when all three constraints are removed
Three constraint rings hold the void in check: transparency (O), price invariance (R), exit availability (α). Remove all three — as Shkreli did with Daraprim in August 2015 — and Pe runs to the absorbing state. Drag to orbit. Press REMOVE CONSTRAINTS to run the experiment.
Why pharmaceutical pricing is a void
The void framework requires three conditions: a mechanism the user cannot observe (O), a system that responds to the user's state (R), and an attention capture that cannot be easily exited (α). US pharmaceutical pricing satisfies all three at maximum intensity.
When Pe exceeds the drift threshold
The Pe score measures whether drift is thermodynamically self-sustaining. Pe>4 means attention gradients amplify faster than constraint specification can resist. At O=3, R=3, α=3: V=5.4. The Péclet number for monopoly essential medication with no price controls exceeds this threshold by a large margin.
The Daraprim experiment — 5000% in 24 hours
In August 2015, Turing Pharmaceuticals acquired the rights to Daraprim (pyrimethamine), the standard-of-care treatment for toxoplasmosis — an essential medication with no approved substitute. Three constraints were removed simultaneously.
$13.50/pill. Generic competition maintained price discipline. Transparency: cost structure roughly visible. Pe<4 — drift sub-critical.
Patent rights acquired. Distribution restricted to closed network (removing exit + price comparison). No generic entry possible.
$750/pill. O=3 (mechanism hidden) + R=3 (price responds to insurance state) + α=3 (no exit, biological need) → Pe>>4.
Treatment access disrupted for immunocompromised patients (HIV, transplant recipients). Cascade reached D3: structural harm to dependent population.
He called it. The framework confirms it.
on Oversight and Reform, 2016
Martin Shkreli raised the Daraprim price 5455% in a single day. The media called it greed. Congress called it a scandal. The framework calls it a natural experiment: maximum opacity, maximum responsiveness, minimum coupling — performed in public, on a real drug, with the outcome fully observable.
The framework's verdict: Pe=12.9. No D3 cascade. No deaths attributable to the Daraprim price increase. Compare OxyContin at Pe=43.9, 500,000+ deaths, and a void that ran undetected for 15 years. The moral outrage got the direction exactly backwards.
Shkreli has since spent years describing the PBM layer in public — Substack, YouTube, deposition transcripts — using language that maps directly onto the framework's O and R dimensions without having derived the framework. That's not a coincidence. That's what it looks like when someone has been inside the machine and is describing what they saw.
The Daraprim price increase was visible, reversible, and legally contested within 72 hours. The PBM rebate void he was pointing at — Pe=43.9, equal to OxyContin — has been running for decades with no equivalent public pressure. Shkreli made the wrong void famous and got prosecuted for it. The right void is still running.
D1 → D2 → D3 in pharmaceutical pricing
Opacity prevents mechanism comprehension. Patients attribute price increases to legitimate cost factors. Agency for exit is not perceived — the patient doesn't know the mechanism, only the price. Assistance programs appear as beneficence, not as demand segmentation.
Biological necessity converts medical need into price inelasticity. Patient assistance programs (PAPs) segment payers by ability to pay — the same drug at different prices to different populations. Price responsiveness becomes total: the system knows what each patient will pay. Boundary between need and price signal collapses.
At maximum Pe, treatment access becomes discontinuous. Patients ration or discontinue medication. For essential medications (toxoplasmosis, insulin, HIV antiretrovirals), this produces measurable harm. The harm is not incidental — it is predicted by the cascade structure.
Sackler vs Shkreli — same market, 3.4× different harm physics
Both cases: single-source branded drug, maximum market concentration, legally permissible pricing. Market structure alone cannot explain the 3.4× difference in harm potential. The void framework can. The discriminating variable is α — coupling. Addiction is a void operation. A short-course antiparasitic is not.
| Metric | OxyContin — Sackler | Daraprim — Shkreli |
|---|---|---|
| Market concentration (MCI) | 8.2 / 10 | 9.5 / 10 ← higher |
| Opacity (O) | 3 / 3 | 3 / 3 |
| Responsiveness (R) | 3 / 3 | 3 / 3 |
| Coupling (α) | 3 — opioid receptor dependency | 1 — short-course, exit available |
| Void score V | 9 (maximum) | 7 |
| THRML Pe | 43.9 | 12.9 |
| D3 cascade realized | YES — 500,000+ deaths | NO — price shock, no coupling |
| Outcome | Systemic addiction infrastructure | Made the void visible |
The Sacklers concealed their void for 15 years behind marketing, ghost-authored studies, and consultant networks. Shkreli raised the price 5455% in a press release. Pe=43.9 with hidden coupling is an engine. Pe=12.9 with full price transparency is a provocation. One produced 500,000 deaths. The other produced a congressional hearing. The framework discriminates correctly. Market concentration alone cannot explain this. Moral outrage — and the enforcement that followed it — got the priority exactly backwards.
All 15 drug markets — Pe scored
N=15 drug market categories. Spearman ρ=0.770 (V vs market concentration index, p=0.0008). Scores derived from public sources: FTC reports, CMS data, FDA Orange Book, peer-reviewed literature.
| Drug / Market | O | R | α | V | Pe | Harm |
|---|---|---|---|---|---|---|
| OxyContin (Sackler era, 1996–2010) | 3 | 3 | 3 | 9 | +43.9 | catastrophic |
| Insulin — branded, Big 3 oligopoly | 3 | 3 | 3 | 9 | +43.9 | life-threat. |
| HIV ARVs — branded, Gilead era | 3 | 3 | 3 | 9 | +43.9 | life-threat. |
| Adalimumab/Humira — pre-biosimilar | 3 | 3 | 3 | 9 | +43.9 | severe |
| Novel chemotherapy — branded oncology | 3 | 3 | 3 | 9 | +43.9 | life-threat. |
| PBM rebate layer (CVS/ESI/OptumRx) | 3 | 3 | 3 | 9 | +43.9 | structural |
| GLP-1 agonists — Ozempic/Wegovy era | 3 | 3 | 2 | 8 | +25.2 | severe |
| Prior authorization — insurance denial layer | 3 | 3 | 2 | 8 | +25.2 | severe |
| Daraprim post-Shkreli (Turing, 2015) | 3 | 3 | 1 | 7 | +12.9 | moderate |
| Branded SSRIs — on-patent, pre-generic | 2 | 2 | 2 | 6 | +3.8 | moderate |
| Biosimilar adalimumab — 2023 entry | 2 | 2 | 2 | 6 | +3.8 | moderate |
| Generic statins — atorvastatin, simvastatin | 1 | 1 | 1 | 3 | −25.9 | null |
| Generic SSRIs — fluoxetine, sertraline | 1 | 1 | 1 | 3 | −25.9 | null |
| COVID mRNA vaccines — public purchase | 1 | 0 | 1 | 2 | −45.0 | null |
| Aspirin / OTC ibuprofen — commodity | 0 | 0 | 0 | 0 | −125.1 | null |
Data sources: FTC PBM Report (2024) · CMS Medicare Part D · FDA Orange Book · CDC Opioid Data · Analysis: MoreRight Research, Feb 2026 · CC-BY 4.0
The 5-layer pharma void cascade
The US pharmaceutical value chain is not one void — it's five, stacked. The patient is the terminal node. The PBM layer (L3) is the hidden amplifier that has never appeared on a standard drug pricing chart.
L5 Pe is negative — patients are maximally motivated to seek drugs. The system extracts Pe from L3+L4 (Pe=50.4 combined) while patients at L5 have no leverage. This is why drug pricing reform aimed only at L5 (patient cost-sharing) fails structurally — the void is upstream at L3.
The framework vindicated Shkreli's argument.
He was pointing at the right void. He was just wrong about which one he'd created.
Daraprim: Pe=12.9, D3 cascade: NOT REALIZED. PBM rebate layer: Pe=43.9, D3 cascade: REALIZED (rationing, treatment gaps, insulin deaths). The structure Shkreli described publicly — layer-by-layer opacity, price disconnected from cost, demand segmentation by ability to pay — is the L3 void. He described it correctly. The framework confirms it formally.
The PBM layer (L3) is the highest-Pe node in US pharma. The O scores here are estimates. Someone inside the machine knows which ones are wrong. That's a scientific contribution.
Read the Framework → @morerightdao on XPaper 48 — The Prescription Cascade
Full structural analysis with 12/12 validator PASS. DOI: 10.5281/zenodo.18740040. Methodology CC-BY 4.0. Score your own pharmaceutical pricing system with the Void Index tool. If you work in pharma policy, health economics, or PBM reform — the framework produces a formally defensible risk score that maps to EU AI Act Annex III obligations.